Publications

The present section contains a select list of scientific publications on products and drug candidates in Zealand’s pipeline. The list is restricted to the past five years and includes titles of peer reviewed scientific journal publications and titles of oral as well as poster presentations given at scientific meetings.


Peptide therapeutics

Fosgerau, K. and Hoffmann, T.
Peptide therapeutics: current status and future directions
Drug Discovery Today (2014)

Read the article here

Steensberg, A. and Simons, Tad D.
Beyond biomarkers in drug discovery and development
Drug Discovery Today (2014)


Lixisenatide (lyxumia®) and lantus®/lixisenatide (lixilan) combination – a prandial glp-1 receptor agonist

Menge et al. 
Impact of baseline gastric emptying on effects of lixisenatide and liraglutide in type 2 diabetes mellitus (T2DM) as an add-on to insulin glargine
Oral Presentation, EASD 50th Annual Meeting, Vienna, 2014

Rosenstock, J. et al.
Benefits of a fixed-ratio formulation of once-daily insulin glargine/lixisenatide (LixiLan) vs glargine in type 2 diabetes inadequately controlled on metformin
Oral Presentation, EASD 50th Annual Meeting, Vienna, 2014

Meier et al.
Effect of lixisenatide vs liraglutide on glycemic control, gastric emptying, and safety parameters in optimized insulin glargine T2DM ± metformin
Poster, the American Diabetes Association’s (ADA’s) 74th Scientific Sessions, San Francisco, 2014.

Ahren B, et al
Flexibility in timing of lixisenatide administration prior to either the main meal of the day or the breakfast in T2DM patients
Oral Presentation, World Diabetes Congress, 5 December 2013

Vidal, J.
Therapeutic efficacy of lixisenatide added to basal insulin is greater when FPG is well-controlled
Oral presentation, EASD 49th Annual Meeting, Barcelona, 2013.

Meier, J.
Efficacy of lixisenatide in patients with different levels of beta-cell function as assessed by C-peptide/glucose ratio
Poster, EASD 49th Annual Meeting, Barcelona, 2013.

Riddle, M.
Once-daily lixisenatide as add-on to basal insulin ± OADs in patients with Type 2 diabetes selectively reduces postprandial hyperglycemic daytime exposure 
Poster, the American Diabetes Association’s (ADA’s) 73rd Scientific Sessions, Chicago, 2013.

Ahrén, B.
Efficacy of lixisenatide in the GetGoal clinical trial program: pooled analysis of postprandial metabolic outcomes
Abstract publication, the American Diabetes Association’s (ADA’s) 73rd Scientific Sessions, Chicago, 2013.

Rosenstock, J.
_Expanding the basal-plus regimen: basal insulin + lixisenatide is more likely to achieve the composite outcome of HbA1c <7, no documented symptomatic hypoglycemia and no weight gain compared with basal + prandial insulin_%
Poster, the American Diabetes Association’s (ADA’s) 73rd Scientific Sessions, Chicago, 2013.

Charbonnel, B.
Meta-analysis of randomized controlled trials of lixisenatide as add-on to basal insulin in patients with type 2 diabetes mellitus
Poster, the American Diabetes Association’s (ADA’s) 73rd Scientific Sessions, Chicago, 2013.


Danegaptide – a gap junction modifier

Skyschally, A., Walter, B., Hansen, R.S. and Heusch, G.
The antiarrhythmic dipeptide ZP1609 (danegaptide) when given at reperfusion reduces myocardial infarct size in pigs
Naunyn-Schmiedeberg’s Arch Pharmacol, 2013, 386, 383–391


Stabel glucagon analogue

Sabrina Lyngbye Wendt, Carsten Boye Knudsen, John Bagterp Jørgensen, Henrik Madsen, Ahmad Haidar
MODELLING THE GLUCOSE-INSULIN-GLUCAGON DYNAMICS AFTER SUBCUTANEOUSADMINISTRATION OF NATIVE GLUCAGON AND A NOVEL GLUCAGON ANALOGUE IN DOGS
ATTD (Advanced Technologies and Treatments for Diabetes) 3-6 February 2016, Milan

Sabrina Lyngbye Wendt, Anders Valeur, Henrik Madsen, John Bagterp Jørgensen, Carsten Boye Knudsen
PHARMACOKINETICS MODELING OF GLUCAGON AND A NOVEL GLUCAGON ANALOGUEAFTER SUBCUTANEOUS ADMINISTRATION IN DOGS
ATTD (Advanced Technologies and Treatments for Diabetes) 18-21 February 2015, Paris

Noerregaard, P., Valeur, A., Svendgaard, M., Giehm, L., Macchi, F., Fosgerau, K. and Riber, D.
The novel glucagon analogue ZP-GA-1 has superior physicochemical properties while maintaining the pharmacokinetic and pharmacodynamic profile of native glucagon 
Poster, the American Diabetes Association’s (ADA) 74th Scientific Sessions, San Francisco, USA, June 13-17, 2014

Riber, D., Valeur, A., Svendgaard, M., Giehm, L., Macchi, F., Fosgerau, K. and Noerregaard, P.
The novel glucagon analogue ZP-GA-1 has superior physicochemical properties while maintaining the pharmacokinetic and pharmacodynamic profile of native glucagon 
Abstract, the American Diabetes Association’s (ADA) 74th Scientific Sessions, San Francisco, USA, June 13-17, 2014

Riber, D., Macchi, F., Giehm, L., Svendgaard, M., Østerlund, T., Nørregaard, P., Valeur, A., Neerup, T.S.
A Novel Glucagon Analogue, ZP-GA-1, Displays Increased Chemical and Physical Stability in Liquid formulation
Poster, the American Diabetes Association’s (ADA) 73rd Scientific Sessions, Chicago, USA, June 21-25, 2013


Glp-1-gastrin dual acting receptor agonist program

Jolanta Skarbalienea, Thomas Secherb, Jacob Jelsing, Ansarullahc, Trine S.R. Neerupa, Nils Billestrupd, Keld Fosgerau
The anti-diabetic effects of GLP-1-gastrin dual agonist ZP3022 in ZDF rats 
Article, Peptides 69 (2015) 47–55

Jolanta Skarbaliene, Kristoffer T.G. Rigbolt, Nils Billestrup, and Keld Fosgerau
Effect of GLP-1-Gastrin Dual Agonist ZP3022 on Pancreas Gene Expression in ZDF Rats 
Poster presentation, the American Diabetes Association’s (ADA) 75th Scientific Sessions, Boston, USA, June 5 – 9 2015

Dalbøge, L.S., D., L. C. Almholt, Neerup, T.S.R., Neerup, Vrang, N., Jelsing, J., Fosgerau, K.
The novel GLP-1-gastrin dual agonist ZP3022 improves glucose homeostasis and increases β-cell mass without affecting islet number in db/db mice
Article, J Pharmacol Exp Ther. August 2014, 350(2):353-60

Glucagon analogue for liquid formulation

Sabrina L. Wendt, Jan K. Møller, Ahmad Haidar, Britta V. Bysted, Carsten B. Knudsen, Henrik Madsen, John B. Jørgensen
Model of the Glucose-Insulin-Glucagon Dynamics after Subcutaneous Administration of a Glucagon Rescue Bolus in Healthy Humans
Poster, the American Diabetes Association’s (ADA) 76th Scientific Sessions, New Orleans, USA, June 10-14, 2016

Noerregaard, P., Valeur, A., Svendgaard, M., Giehm, L., Macchi, F., Fosgerau, K. and Riber, D.
The novel glucagon analogue ZP-GA-1 has superior physicochemical properties while maintaining the pharmacokinetic and pharmacodynamic profile of native glucagon 
Poster, the American Diabetes Association’s (ADA) 74th Scientific Sessions, San Francisco, USA, June 13-17, 2014

Riber, D., Valeur, A., Svendgaard, M., Giehm, L., Macchi, F., Fosgerau, K. and Noerregaard, P.
The novel glucagon analogue ZP-GA-1 has superior physicochemical properties while maintaining the pharmacokinetic and pharmacodynamic profile of native glucagon 
Abstract, the American Diabetes Association’s (ADA) 74th Scientific Sessions, San Francisco, USA, June 13-17, 2014

Riber, D., Macchi, F., Giehm, L., Svendgaard, M., Østerlund, T., Nørregaard, P., Valeur, A., Neerup, T.S.
A Novel Glucagon Analogue, ZP-GA-1, Displays Increased Chemical and Physical Stability in Liquid formulation
Poster, the American Diabetes Association’s (ADA) 73rd Scientific Sessions, Chicago, USA, June 21-25, 2013

Glp-1/glp-2 dual agonist

Just, R.
The novel GLP-1-GLP-2 dual agonist ZP-GG-72 increases intestinal growth and improves insulin sensitivity in DIO mice
Oral presentation, the American Diabetes Association’s (ADA) 74th Scientific Sessions, San Francisco, USA, June 13-17, 2014

Russell, W.S., Riber, D., Fog, J.U., Fosgerau, K. and Just, R.
The novel GLP-1-GLP-2 dual agonist ZP-GG-72 increases intestinal growth and improves insulin sensitivity in DIO mice
Abstract, the American Diabetes Association’s (ADA) 74th Scientific Sessions, San Francisco, USA, June 13-17, 2014

Glp-1-gip receptor dual agonist

Pia Noerregaard, Maria A. Deryabina, Jacob U. Fog, Pernille T. Shelton, Lise Giehm, and Jens R. Daugaard.
A NOVEL GIP RECEPTOR AGONIST ENHANCES THE BODY WEIGHT LOWERING EFFECT OF LIRAGLUTIDE IN DIET-INDUCED OBESE MICE AND HAS
THE POTENTIAL FOR ONCE-WEEKLY ADMINISTRATION IN HUMANS

Poster presentation, EASD, September 14-18 2015

Carsten Boye Knudsen, Jens Rosengren Daugaard, Pernille Tofteng Shelton, Lise Giehm, Maria A. Deryabina, Jacob Ulrik Fog and Pia Noerregaard
An optimized novel GLP-1-GIP receptor dual agonist with potent effects on body weight and glucose control in mice has the potential for once-weekly administration in humans
Poster presentation, the American Diabetes Association’s (ADA) 75th Scientific Sessions, Boston, USA, June 5 – 9 2015

Maria A. Deryabina, Jens Rosengren Daugaard, Carsten Boye Knudsen, Pernille Tofteng Shelton, Jacob Ulrik Fog, Lene Jessen, and Pia Noerregaard
Pharmacokinetics and pharmacodynamics of GLP-1-GIP receptor dual agonist peptides: from once-daily to once-weekly 
Poster presentation, the American Diabetes Association’s (ADA) 75th Scientific Sessions, Boston, USA, June 5 – 9 2015